IRONWOOD PHARMACEUTICALS INC (IRWD) Stock Price, Quote, News and Overview
NASDAQ:IRWD - Nasdaq - US46333X1081 - Common Stock - Currency: USD
IRWD Quote, Performance and Key Statistics
0.6524
+0.04 (+6.62%)
The current stock price of IRWD is 0.6524 USD. In the past month the price decreased by -9.31%. In the past year, price decreased by -89.04%.
IRWD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18 | 327.00B | ||
| AMGN | AMGEN INC | 13.25 | 147.86B | ||
| GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
| ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
| NTRA | NATERA INC | N/A | 21.01B | ||
| BIIB | BIOGEN INC | 8.25 | 19.13B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B |
Related stock screener links
About IRWD
Company Profile
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 253 full-time employees. The company went IPO on 2010-02-03. The company is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. The company is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. The company is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. The company is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.
Company Info
IRONWOOD PHARMACEUTICALS INC
100 Summer Street, Suite 2300
Boston MASSACHUSETTS 02110 US
CEO: Mark Mallon
Employees: 253
Phone: 16176217722
IRONWOOD PHARMACEUTICALS INC / IRWD FAQ
What is the stock price of IRONWOOD PHARMACEUTICALS INC today?
The current stock price of IRWD is 0.6524 USD. The price increased by 6.62% in the last trading session.
What is the ticker symbol for IRONWOOD PHARMACEUTICALS INC stock?
The exchange symbol of IRONWOOD PHARMACEUTICALS INC is IRWD and it is listed on the Nasdaq exchange.
On which exchange is IRWD stock listed?
IRWD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IRONWOOD PHARMACEUTICALS INC stock?
12 analysts have analysed IRWD and the average price target is 5.24 USD. This implies a price increase of 702.57% is expected in the next year compared to the current price of 0.6524. Check the IRONWOOD PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IRONWOOD PHARMACEUTICALS INC worth?
IRONWOOD PHARMACEUTICALS INC (IRWD) has a market capitalization of 105.57M USD. This makes IRWD a Micro Cap stock.
How many employees does IRONWOOD PHARMACEUTICALS INC have?
IRONWOOD PHARMACEUTICALS INC (IRWD) currently has 253 employees.
What are the support and resistance levels for IRONWOOD PHARMACEUTICALS INC (IRWD) stock?
IRONWOOD PHARMACEUTICALS INC (IRWD) has a resistance level at 0.66. Check the full technical report for a detailed analysis of IRWD support and resistance levels.
Is IRONWOOD PHARMACEUTICALS INC (IRWD) expected to grow?
The Revenue of IRONWOOD PHARMACEUTICALS INC (IRWD) is expected to decline by -23.71% in the next year. Check the estimates tab for more information on the IRWD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IRONWOOD PHARMACEUTICALS INC (IRWD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IRWD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IRWD, evaluating the profitability, health, valuation and growth aspects
- IRONWOOD PHARMACEUTICALS INC (IRWD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IRONWOOD PHARMACEUTICALS INC (IRWD) Sales and EPS estimates to see what analysts future expectations are.
- IRONWOOD PHARMACEUTICALS INC (IRWD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IRONWOOD PHARMACEUTICALS INC (IRWD) Insider and Institutional Ownership to learn about the owners and their transactions.
- IRONWOOD PHARMACEUTICALS INC (IRWD) Stock Chart to make your own analysis
- IRONWOOD PHARMACEUTICALS INC (IRWD) Latest news and press-releases to stay up to date.
Does IRONWOOD PHARMACEUTICALS INC (IRWD) stock pay dividends?
IRWD does not pay a dividend.
When does IRONWOOD PHARMACEUTICALS INC (IRWD) report earnings?
IRONWOOD PHARMACEUTICALS INC (IRWD) will report earnings on 2025-08-06, before the market open.
What is the Price/Earnings (PE) ratio of IRONWOOD PHARMACEUTICALS INC (IRWD)?
IRONWOOD PHARMACEUTICALS INC (IRWD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.1).
What is the Short Interest ratio of IRONWOOD PHARMACEUTICALS INC (IRWD) stock?
The outstanding short interest for IRONWOOD PHARMACEUTICALS INC (IRWD) is 5.57% of its float. Check the ownership tab for more information on the IRWD short interest.
IRWD Technical Analysis
IRWD Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to IRWD. IRWD has only an average score on both its financial health and profitability.
IRWD Financial Highlights
Over the last trailing twelve months IRWD reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS decreased by -127.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.25% | ||
| ROA | 0.25% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IRWD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to IRWD. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 869% and a revenue growth -23.71% for IRWD